Repens Healthcare India Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 3.51 M
- Company Age 8 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.50 M
- Revenue Growth 73.30%
- Profit Growth 117.85%
- Ebitda 143.17%
- Net Worth 49.66%
- Total Assets 50.92%
About Repens Healthcare India
Repens Healthcare India Private Limited (RHIPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 May 2016 (Eight years and eight months 23 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 3.51 M.
The company currently has active open charges totaling ₹4.50 M.
Sweta Shetty and Pavan Shetty serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U52390MH2016PTC280841
-
Company No.
280841
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 May 2016
-
Date of AGM
24 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Repens Healthcare India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pavan Shetty
|
Managing Director | 10-May-2016 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sweta Shetty
|
Director | 10-May-2016 | Current |
Financial Performance of Repens Healthcare India.
Repens Healthcare India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 73.3% increase. The company also saw a substantial improvement in profitability, with a 117.85% increase in profit. The company's net worth Soared by an impressive increase of 49.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Repens Healthcare India?
In 2023, Repens Healthcare India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.45 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 0.45 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Dec 2019 | Others | ₹4.50 M | Open |
How Many Employees Work at Repens Healthcare India?
Unlock and access historical data on people associated with Repens Healthcare India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Repens Healthcare India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Repens Healthcare India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.